​​ TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s contractility assay to evaluate the safety and efficacy of biopharmaceutical drug candidates.

Calcium is critical to cardiac function because it helps convert electrical signals in heart muscle to mechanical contractions needed for the heart to pump blood. To assess cardiac function properly, it is important to measure contractility and calcium signaling at the same time. However, there have been no models to measure both these functions simultaneously in the lab until now, making it challenging to test the cardiac effects of drug candidates.

Leveraging TARA’s Biowire™ II platform, Cardiotype.Ca™ is the only in vitro assay on the market that is capable of simultaneously measuring calcium signaling and contractile force in 3D engineered human cardiac tissues. Unlike current in vitro and animal models, TARA’s platform uses induced pluripotent stem cells (iPSC) derived from cardiac tissue and possesses the structural, functional, and genetic characteristics of adult human cardiac muscle. The physiologically relevant model enables early cardiac risk assessment of drug discovery candidates and accelerates discovery of novel heart medicines via disease modeling and phenotypic screening capabilities. Cardiotype.Ca™ has already received successful evaluations from several pharmaceutical partners prior to the launch.

“The ability to measure calcium signaling and contractility simultaneously in TARA’s engineered tissue model allows our pharma partners to uncover mechanistic insights about their drug candidates in human-relevant models much earlier in the drug development process, helping to deliver better drugs sooner,” said Michael Graziano, PhD, chief scientific officer of TARA Biosystems.

TARA will be showcasing Cardiotype.Ca™ at the 2019 Safety Pharmacology Society (SPS) Annual Meeting in Barcelona Spain (September 23-25) at Booth #502 and during a sponsored presentation on Tuesday, September 24th at 12:30pm entitled “Using hiPSC-derived Tissues for Cardiac Risk Assessment: Translational Considerations.” To learn more about Cardiotype.Ca™ stop by the booth or contact TARA in advance to schedule a meeting with the team (BD@tarabiosystems.com).

 

About TARA Biosystems

TARA Biosystems, Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and risk assessment. TARA Biosystems offers a high fidelity solution that is based on human iPSC derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac function. The TARA platform allows pharma to access human cardiac information on therapeutics candidates earlier in the drug development cycle.

For more information, please visit: www.tarabiosystems.com.

 

Press Contact:

Ken Li

CG Life

kli@cglife.com

312.532.4675